SemBioSys Partnership Opportunities
Partnerships are a fundamental element of SemBioSys' business strategy. They allow SemBioSys to focus on its core capabilities of technology innovation and early-stage product development. SemBioSys seeks strategic partnerships when it has fully utilized internal resources and expertise to minimize the risk and maximize the value of its development programs. SemBioSys selects partners who are best positioned to accelerate late-stage product development and ensure its products have the greatest positive impact on health.
Insulin
SemBioSys is developing a portfolio of low-cost insulin and insulin analogues to combat the global diabetes epidemic. Our insulin portfolio provides an excellent opportunity for strategic partners to enter the multi-billion dollar global insulin market with a competitively advantaged product. We are seeking well-positioned manufacturing and commercialization partners to co-develop plant-derived insulin across the developed and developing world.
Apo AIMilano
SemBioSys is developing Apo AIMilano as the basis for a novel HDL therapy targeting cardiovascular diseases such as heart attack and stroke. Apo AIMilano offers enabling advantages for manufacturing and commercialization of this promising class of therapy. We are seeking partnership with an industry leader in cardiovascular disease to drive the advanced development and commercialization of plant-derived Apo AIMilano.
The SemBioSys Platform
Beyond our current programs, SemBioSys' technologies are applicable to a wide range of product opportunities in areas of human health, veterinary medicine, agricultural biotechnology and industrial processing. Our technology is available for limited or product-focused license, with partnering opportunities being examined on a case-by-case basis.
If you would like more information on partnering with SemBioSys, please contact Abby Garfunkel at 403.250.5424 or garfunkela
.